• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

磷酸泰地唑胺（西沃沙星）：一种用于治疗急性细菌性皮肤及皮肤结构感染的第二代恶唑烷酮类药物。

Tedizolid phosphate (sivextro): a second-generation oxazolidinone to treat acute bacterial skin and skin structure infections.

作者信息

Wong Elaine, Rab Saba

出版信息

P T. 2014 Aug;39(8):555-79.

PMID:25136252
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4123804/
Abstract

Tedizolid phosphate: a second-generation oxazolidinone for acute bacterial skin and skin structure infections.

摘要

磷酸泰地唑胺

一种用于治疗急性细菌性皮肤及皮肤结构感染的第二代恶唑烷酮类药物。

相似文献

1
Tedizolid phosphate (sivextro): a second-generation oxazolidinone to treat acute bacterial skin and skin structure infections.磷酸泰地唑胺（西沃沙星）：一种用于治疗急性细菌性皮肤及皮肤结构感染的第二代恶唑烷酮类药物。
P T. 2014 Aug;39(8):555-79.
2
Tedizolid phosphate for the treatment of acute bacterial skin and skin structure infections.用于治疗急性细菌性皮肤及皮肤结构感染的磷酸特地唑胺
Drugs Today (Barc). 2014 Nov;50(11):729-37. doi: 10.1358/dot.2014.50.11.2233783.
3
Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial.磷酸替加环素与利奈唑胺治疗急性细菌性皮肤和皮肤结构感染：ESTABLISH-1 随机试验。
JAMA. 2013 Feb 13;309(6):559-69. doi: 10.1001/jama.2013.241.
4
[Pharmacological action and clinical effect of tedizolid phosphate (SIVEXTRO Tablets 200 mg, for iv infusion 200 mg), a novel oxazolidinone-class antibacterial drug].新型恶唑烷酮类抗菌药物磷酸特地唑胺（200毫克西沃替尼片，静脉输注200毫克）的药理作用及临床效果
Nihon Yakurigaku Zasshi. 2020;155(5):332-339. doi: 10.1254/fpj.20013.
5
Potential role of tedizolid phosphate in the treatment of acute bacterial skin infections.磷酸特地唑胺在急性细菌性皮肤感染治疗中的潜在作用。
Drug Des Devel Ther. 2013 Apr 3;7:243-65. doi: 10.2147/DDDT.S30728. Print 2013.
6
Tedizolid phosphate for the management of acute bacterial skin and skin structure infections: efficacy summary.磷酸替考拉宁治疗急性细菌性皮肤和皮肤结构感染的疗效总结。
Clin Infect Dis. 2014 Jan;58 Suppl 1:S43-50. doi: 10.1093/cid/cit617.
7
Tedizolid: The First Once-Daily Oxazolidinone Class Antibiotic.替加环素：首个每日一次使用的恶唑烷酮类抗生素。
Clin Infect Dis. 2015 Oct 15;61(8):1315-21. doi: 10.1093/cid/civ501. Epub 2015 Jun 23.
8
Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens.替考拉宁：一种新型噁唑烷酮类药物，对多种耐药革兰阳性病原体具有强大的活性。
Drugs. 2015 Feb;75(3):253-70. doi: 10.1007/s40265-015-0352-7.
9
Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial.替考拉宁治疗 6 天与利奈唑胺治疗 10 天治疗急性细菌性皮肤和皮肤结构感染（ESTABLISH-2）：一项随机、双盲、III 期、非劣效性试验。
Lancet Infect Dis. 2014 Aug;14(8):696-705. doi: 10.1016/S1473-3099(14)70737-6. Epub 2014 Jun 5.
10
Sivextro (Tedizolid Phosphate) Approved for the Treatment of Adults with Acute Bacterial Skin and Skin-Structure Infections.赛福喜（磷酸泰地唑胺）获批用于治疗成人急性细菌性皮肤及皮肤结构感染。
Am Health Drug Benefits. 2015 Mar;8(Spec Feature):111-5.

引用本文的文献

1
Antibiotic stewardship in the emergency department setting: Focus on oral antibiotic selection for adults with skin and soft tissue infections.急诊科的抗生素管理：重点关注成人皮肤软组织感染的口服抗生素选择。
Am J Health Syst Pharm. 2024 Oct 23;81(21):e677-e683. doi: 10.1093/ajhp/zxae163.
2
Composing On-Program Triggers and On-Demand Stimuli into Biosensor Drug Carriers in Drug Delivery Systems for Programmable Arthritis Therapy.在用于可编程性关节炎治疗的药物递送系统中，将程序内触发器和按需刺激因素整合到生物传感器药物载体中。
Pharmaceuticals (Basel). 2022 Oct 27;15(11):1330. doi: 10.3390/ph15111330.
3
Population Pharmacokinetics, Exposure-Response, and Probability of Target Attainment Analyses for Tedizolid in Adolescent Patients with Acute Bacterial Skin and Skin Structure Infections.泰地唑胺治疗青少年急性细菌性皮肤和皮肤结构感染的群体药代动力学、暴露-反应和目标达成概率分析。
Antimicrob Agents Chemother. 2021 Nov 17;65(12):e0089521. doi: 10.1128/AAC.00895-21. Epub 2021 Sep 13.
4
Radiolabeled Tedizolid Phosphate Liposomes for Topical Application: Design, Characterization, and Evaluation of Cellular Binding Capacity.放射性标记磷酸替考拉宁脂质体用于局部应用：细胞结合能力的设计、表征和评价。
AAPS PharmSciTech. 2021 Feb 2;22(2):62. doi: 10.1208/s12249-020-01917-4.
5
Antimicrobial Stewardship Program in Critical Care-Need of the Hour.重症监护中的抗菌药物管理计划——刻不容缓的需求。
Indian J Crit Care Med. 2020 Sep;24(9):847-854. doi: 10.5005/jp-journals-10071-23557.
6
Novel Antibiotics for Multidrug-Resistant Gram-Positive Microorganisms.用于多重耐药革兰氏阳性微生物的新型抗生素
Microorganisms. 2019 Aug 18;7(8):270. doi: 10.3390/microorganisms7080270.
7
Pharmacokinetics of Tedizolid in Plasma and Sputum of Adults with Cystic Fibrosis.特立唑胺在囊性纤维化成人患者血浆和痰液中的药代动力学。
Antimicrob Agents Chemother. 2018 Aug 27;62(9). doi: 10.1128/AAC.00550-18. Print 2018 Sep.
8
and Activities of DS-2969b, a Novel GyrB Inhibitor, and Its Water-Soluble Prodrug, DS11960558, against Methicillin-Resistant Staphylococcus aureus.新型 GyrB 抑制剂 DS-2969b 及其水溶性前药 DS11960558 对耐甲氧西林金黄色葡萄球菌的活性。
Antimicrob Agents Chemother. 2018 May 25;62(6). doi: 10.1128/AAC.02556-17. Print 2018 Jun.
9
In Vivo Activity of LCB 01-0699, a Prodrug of LCB 01-0648, against Staphylococcus aureus.LCB 01-0699 前药（LCB 01-0648）对金黄色葡萄球菌的体内活性。
Molecules. 2017 Nov 29;22(12):2096. doi: 10.3390/molecules22122096.
10
Destination of aminoglycoside antibiotics in the 'post-antibiotic era'.“后抗生素时代”氨基糖苷类抗生素的归宿
J Antibiot (Tokyo). 2017 Oct 25. doi: 10.1038/ja.2017.117.

本文引用的文献

1
Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial.替考拉宁治疗 6 天与利奈唑胺治疗 10 天治疗急性细菌性皮肤和皮肤结构感染（ESTABLISH-2）：一项随机、双盲、III 期、非劣效性试验。
Lancet Infect Dis. 2014 Aug;14(8):696-705. doi: 10.1016/S1473-3099(14)70737-6. Epub 2014 Jun 5.
2
FDA guidance for ABSSSI trials: implications for conducting and interpreting clinical trials.FDA 指导意见下的 ABSSSI 临床试验：对临床试验开展和解读的影响。
Clin Infect Dis. 2014 Jan;58 Suppl 1:S4-9. doi: 10.1093/cid/cit612.
3
In vitro, in vivo, and clinical studies of tedizolid to assess the potential for peripheral or central monoamine oxidase interactions.体外、体内和临床研究替加环素，以评估潜在的外周或中枢单胺氧化酶相互作用。
Antimicrob Agents Chemother. 2013 Jul;57(7):3060-6. doi: 10.1128/AAC.00431-13. Epub 2013 Apr 22.
4
Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial.磷酸替加环素与利奈唑胺治疗急性细菌性皮肤和皮肤结构感染：ESTABLISH-1 随机试验。
JAMA. 2013 Feb 13;309(6):559-69. doi: 10.1001/jama.2013.241.
5
Comparative pharmacodynamics of the new oxazolidinone tedizolid phosphate and linezolid in a neutropenic murine Staphylococcus aureus pneumonia model.新恶唑烷酮类药物替加环素磷酸盐与利奈唑胺在中性粒细胞减少的金黄色葡萄球菌肺炎小鼠模型中的比较药效学研究。
Antimicrob Agents Chemother. 2012 Nov;56(11):5916-22. doi: 10.1128/AAC.01303-12. Epub 2012 Sep 10.
6
Activity of tedizolid phosphate (TR-701) in murine models of infection with penicillin-resistant and penicillin-sensitive Streptococcus pneumoniae.磷酸泰地唑利（TR-701）在耐青霉素和青霉素敏感肺炎链球菌感染的小鼠模型中的活性。
Antimicrob Agents Chemother. 2012 Sep;56(9):4713-7. doi: 10.1128/AAC.00346-12. Epub 2012 Jun 19.
7
Comparative efficacies of human simulated exposures of tedizolid and linezolid against Staphylococcus aureus in the murine thigh infection model.替加环素与利奈唑胺在小鼠大腿感染模型中抗金黄色葡萄球菌的人体模拟暴露比较疗效。
Antimicrob Agents Chemother. 2012 Aug;56(8):4403-7. doi: 10.1128/AAC.00122-12. Epub 2012 Jun 11.
8
Skin and soft tissue concentrations of tedizolid (formerly torezolid), a novel oxazolidinone, following a single oral dose in healthy volunteers.健康志愿者单次口服替加环素（原称替唑肟）后的皮肤和软组织浓度。
Int J Antimicrob Agents. 2012 Jul;40(1):51-4. doi: 10.1016/j.ijantimicag.2012.03.006. Epub 2012 May 13.
9
Pulmonary disposition of tedizolid following administration of once-daily oral 200-milligram tedizolid phosphate in healthy adult volunteers.健康成年志愿者口服每日一次 200 毫克磷酸替加环素后的肺部药物处置。
Antimicrob Agents Chemother. 2012 May;56(5):2627-34. doi: 10.1128/AAC.05354-11. Epub 2012 Feb 13.
10
Tedizolid (TR-701): a new oxazolidinone with enhanced potency.替加环素（TR-701）：一种具有增强效力的新型恶唑烷酮类药物。
Expert Opin Investig Drugs. 2012 Apr;21(4):515-22. doi: 10.1517/13543784.2012.660250. Epub 2012 Feb 13.